|Dr. Steven C. Quay M.D., Ph.D., FCAP||Chairman, Chief Exec. Officer, Pres and Treasurer||830.6k||N/A||1951|
|Mr. Kyle Guse||Chief Financial Officer, Gen. Counsel and Sec.||544.6k||N/A||1964|
|Ms. Janet Rose Rea||Sr. VP of Regulatory, Quality & Clinical Affairs||N/A||N/A||N/A|
|Mr. Pieter Van Der Poel||VP of European Commercial Operations||N/A||N/A||1963|
|Dr. Jack Cuzick Ph.D., FRS, FMedSci, FRCP (hon)||Scientific Advisor||N/A||N/A||N/A|
Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Atossa Genetics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.